Search

Novocure Ltd

Closed

SectorHealthcare

16.3 3.95

Overview

Share price change

24h

Current

Min

16.26

Max

16.41

Key metrics

By Trading Economics

Income

55M

-16M

Sales

9.5M

184M

EPS

-0.13

Profit margin

-8.529

Employees

1,605

EBITDA

53M

-11M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+79.99% upside

Dividends

By Acuity

Next Earnings

29 Oct 2026

Market Stats

By TradingEconomics

Market Cap

-62M

1.8B

Previous open

12.35

Previous close

16.3

News Sentiment

By Acuity

55%

45%

252 / 340 Healthcare

Novocure Ltd Chart

Past performance is not a reliable indicator of future results.

Related News

8 Aug 2026, 00:01 UTC

Novocure Ltd. shares were roughly flat in after-market hours. The stock is near the lower end of its one-month range, despite being above its 20-day average.

7 Aug 2026, 23:11 UTC

Novocure Ltd. shares are lower in after-market trading, reflecting a decline since Friday's close and remaining near the lower end of their one-month range.

6 Aug 2026, 19:36 UTC

Novocure Ltd. shares are trading lower, reaching a session low and remaining below the 20-day moving average during Thursday's trading session.

5 Aug 2026, 19:56 UTC

Novocure Ltd. shares are lower today, trading below their 20-day moving average and near the lower end of their one-month range.

4 Aug 2026, 21:02 UTC

Novocure Ltd. shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market volatility and fluctuating crude oil prices.

3 Aug 2026, 20:06 UTC

Novocure Ltd. shares are higher today, reflecting broader market gains amid positive investor sentiment and declines in oil prices.

31 Jul 2026, 19:46 UTC

Novocure Ltd. shares are lower today, retracing from earlier session highs amid rising bond yields and ongoing inflation concerns. The stock remains below its 20-day moving average.

30 Jul 2026, 19:39 UTC

Novocure Ltd shares are higher today, recovering from an early dip. The stock remains below its 20-day moving average amid a trend of lower closes.

29 Jul 2026, 18:55 UTC

Novocure Ltd's shares are declining today, reversing from a recent trend of higher daily closes. Earlier in the session, the stock briefly rebounded.

28 Jul 2026, 23:31 UTC

Novocure Ltd. shares are lower in after-market hours, continuing a decline over the past four sessions and trading below the 20-day moving average.

27 Jul 2026, 19:06 UTC

Novocure Ltd. shares are lower today amid a broader market decline influenced by a significant drop in crude oil prices.

24 Jul 2026, 19:41 UTC

News
Social Media

Novocure Ltd's stock is lower following its Q2 earnings report, despite a narrower loss and revenue beat. Analysts lowered price targets amid ongoing investor concerns.

22 Jul 2026, 20:04 UTC

Shares of Novocure Ltd. are lower today, continuing a decline since Tuesday's close amid broader market uncertainty ahead of the Federal Reserve meeting.

20 Jul 2026, 14:36 UTC

Novocure Ltd. is trading higher since Friday's close, despite pulling back from an early session high amid broader market volatility from geopolitical tensions.

Peer Comparison

Price change

Novocure Ltd Forecast

Price Target

By TipRanks

79.99% upside

12 Months Forecast

Average 29.5 USD  79.99%

High 52 USD

Low 17 USD

Based on 4 Wall Street analysts offering 12 month price targets forNovocure Ltd - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Sentiment

By Acuity

252 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Novocure Ltd

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
help-icon Live chat